a year ago

Samphire Neuroscience Raises €2.1 Million for PMS and Menstrual Pain Wearable

  • Samphire Neuroscience, a UK-based medtech startup, has raised €2.1 million in pre-seed funding to launch Nettle, their medical-grade neurostimulation wearable designed to target PMS and menstrual pain

  • The funding round was led by SOSV and included participation from other venture firms like FIRSTPICK, Afterwork, Seaside, Ayuh, and CVX Ventures, as well as angel investors such as Dr Pamela Walker and Rowena Ironside

  • Nettle uses transcranial direct current stimulation (tDCS) to modulate neuronal activity in the prefrontal and motor cortex, aiming to manage both chronic pain and mood symptoms associated with PMS and menstrual pain

  • The company emphasizes the need for better treatment options for women's health, highlighting the underfunding and under-research in this area

  • They believe their brain-based approach can lead to breakthroughs in understanding and treating women's health issues.

      • ProblemHealthcare

      "Many women experience severe menstrual cramps and PMS symptoms, leading to significant pain, discomfort, and lost productivity. Current medical interventions often have adverse side effects or require significant sacrifices, leaving women with limited effective and safe treatment options."

      Solution

      "Samphire Neuroscience is developing a medical-grade neurostimulation wearable called Nettle that targets both the prefrontal cortex and motor cortex to manage chronic pain and mood symptoms associated with PMS and menstrual pain. The device uses transcranial direct current stimulation (tDCS) to modulate neuronal activity and increase neuroplasticity, offering a non-invasive and potentially more effective alternative to traditional treatments."

      Covered on